SK9812003A3 - New use of iloperidone - Google Patents
New use of iloperidone Download PDFInfo
- Publication number
- SK9812003A3 SK9812003A3 SK981-2003A SK9812003A SK9812003A3 SK 9812003 A3 SK9812003 A3 SK 9812003A3 SK 9812003 A SK9812003 A SK 9812003A SK 9812003 A3 SK9812003 A3 SK 9812003A3
- Authority
- SK
- Slovakia
- Prior art keywords
- disorders
- treatment
- platform
- iloperidone
- agents
- Prior art date
Links
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 title claims abstract description 6
- 229960003162 iloperidone Drugs 0.000 title abstract description 3
- 230000003542 behavioural effect Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 abstract description 4
- 208000019022 Mood disease Diseases 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091002531 OF-1 protein Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000036753 Schizophrenia, disorganised type Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000026725 cyclothymic disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000035873 hypermotility Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0102841.4A GB0102841D0 (en) | 2001-02-05 | 2001-02-05 | Organic compounds |
| PCT/EP2002/001130 WO2002064141A1 (fr) | 2001-02-05 | 2002-02-04 | Nouvelle utilisation de l'iloperidone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK9812003A3 true SK9812003A3 (en) | 2004-04-06 |
Family
ID=9908143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK981-2003A SK9812003A3 (en) | 2001-02-05 | 2002-02-04 | New use of iloperidone |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20040072869A1 (fr) |
| EP (1) | EP1370262A1 (fr) |
| JP (1) | JP4278981B2 (fr) |
| KR (1) | KR100851256B1 (fr) |
| CN (1) | CN1226035C (fr) |
| AU (1) | AU2002231766B2 (fr) |
| BR (1) | BR0206918A (fr) |
| CA (1) | CA2434900C (fr) |
| CZ (1) | CZ301357B6 (fr) |
| GB (1) | GB0102841D0 (fr) |
| HU (1) | HUP0303136A3 (fr) |
| IL (3) | IL156819A0 (fr) |
| MX (1) | MXPA03006970A (fr) |
| NO (1) | NO20033163D0 (fr) |
| NZ (1) | NZ527111A (fr) |
| PL (1) | PL362550A1 (fr) |
| RU (1) | RU2301065C2 (fr) |
| SK (1) | SK9812003A3 (fr) |
| TW (1) | TWI322011B (fr) |
| WO (1) | WO2002064141A1 (fr) |
| ZA (1) | ZA200305331B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100063093A1 (en) | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
| WO2006039663A2 (fr) | 2004-09-30 | 2006-04-13 | Vanda Pharmaceuticals, Inc | Methodes d'administration d'iloperidone |
| JP2009538331A (ja) * | 2006-05-22 | 2009-11-05 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | 抑うつ障害のための治療 |
| CN101822673B (zh) * | 2009-03-04 | 2013-09-18 | 北京德众万全药物技术开发有限公司 | 一种含有伊潘立酮的固体药物组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0402644B1 (fr) * | 1989-05-19 | 1995-08-16 | Hoechst-Roussel Pharmaceuticals Incorporated | N-(aryloxyalkyl)hétéroarylpipéridines et -hétéroarylpipérazines, leur procédé de préparation et leur application comme médicaments |
| FR2654104B1 (fr) * | 1989-11-07 | 1992-01-03 | Adir | Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
| AU8778498A (en) * | 1997-08-11 | 1999-03-01 | University Of South Florida Research Foundation, Inc. | Nicotine antagonists for nicotine-responsive neuropsychiatric disorders |
| PT1026950E (pt) * | 1997-10-27 | 2006-06-30 | Cortex Pharma Inc | Tratamento da esquizofrenia com ampaquinas e neurolepticos |
| US5955459A (en) * | 1997-11-26 | 1999-09-21 | Neuromedica, Inc. | Fatty acid-antipsychotic compositions and uses thereof |
| WO2000023057A2 (fr) * | 1998-10-16 | 2000-04-27 | Janssen Pharmaceutica N.V. | Therapie visant a ameliorer la cognition |
| TR200102876T2 (tr) * | 1999-04-07 | 2006-12-21 | Pfizer Products Inc. | Bileşim tedavilerinde CYP2D6 önleyicilerinin kullanılması. |
-
2001
- 2001-02-05 GB GBGB0102841.4A patent/GB0102841D0/en not_active Ceased
-
2002
- 2002-02-01 TW TW091101815A patent/TWI322011B/zh not_active IP Right Cessation
- 2002-02-04 CZ CZ20032114A patent/CZ301357B6/cs not_active IP Right Cessation
- 2002-02-04 IL IL15681902A patent/IL156819A0/xx active IP Right Grant
- 2002-02-04 RU RU2003126175/15A patent/RU2301065C2/ru not_active IP Right Cessation
- 2002-02-04 HU HU0303136A patent/HUP0303136A3/hu unknown
- 2002-02-04 WO PCT/EP2002/001130 patent/WO2002064141A1/fr not_active Ceased
- 2002-02-04 KR KR1020037009134A patent/KR100851256B1/ko not_active Expired - Fee Related
- 2002-02-04 US US10/470,499 patent/US20040072869A1/en not_active Abandoned
- 2002-02-04 MX MXPA03006970A patent/MXPA03006970A/es active IP Right Grant
- 2002-02-04 BR BR0206918-0A patent/BR0206918A/pt not_active Application Discontinuation
- 2002-02-04 SK SK981-2003A patent/SK9812003A3/sk not_active Application Discontinuation
- 2002-02-04 PL PL02362550A patent/PL362550A1/xx not_active Application Discontinuation
- 2002-02-04 AU AU2002231766A patent/AU2002231766B2/en not_active Expired
- 2002-02-04 NZ NZ527111A patent/NZ527111A/en unknown
- 2002-02-04 EP EP02711828A patent/EP1370262A1/fr not_active Withdrawn
- 2002-02-04 CN CNB028043669A patent/CN1226035C/zh not_active Expired - Lifetime
- 2002-02-04 CA CA2434900A patent/CA2434900C/fr not_active Expired - Fee Related
- 2002-02-04 JP JP2002563935A patent/JP4278981B2/ja not_active Expired - Lifetime
-
2003
- 2003-07-07 IL IL156819A patent/IL156819A/en not_active IP Right Cessation
- 2003-07-10 ZA ZA200305331A patent/ZA200305331B/en unknown
- 2003-07-10 NO NO20033163A patent/NO20033163D0/no not_active Application Discontinuation
-
2006
- 2006-05-04 US US11/418,507 patent/US20060205786A1/en not_active Abandoned
-
2007
- 2007-12-21 US US11/962,893 patent/US20080103177A1/en not_active Abandoned
- 2007-12-27 IL IL188485A patent/IL188485A0/en not_active IP Right Cessation
-
2009
- 2009-01-23 US US12/358,959 patent/US20090131477A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL156819A0 (en) | 2004-02-08 |
| US20090131477A1 (en) | 2009-05-21 |
| RU2301065C2 (ru) | 2007-06-20 |
| GB0102841D0 (en) | 2001-03-21 |
| WO2002064141A1 (fr) | 2002-08-22 |
| US20040072869A1 (en) | 2004-04-15 |
| AU2002231766B2 (en) | 2005-12-22 |
| RU2003126175A (ru) | 2005-03-10 |
| ZA200305331B (en) | 2004-05-12 |
| US20080103177A1 (en) | 2008-05-01 |
| CN1531432A (zh) | 2004-09-22 |
| IL188485A0 (en) | 2008-03-20 |
| JP4278981B2 (ja) | 2009-06-17 |
| HUP0303136A3 (en) | 2006-05-29 |
| MXPA03006970A (es) | 2003-11-18 |
| HUP0303136A2 (hu) | 2003-12-29 |
| CZ20032114A3 (cs) | 2004-01-14 |
| NZ527111A (en) | 2005-05-27 |
| JP2004517959A (ja) | 2004-06-17 |
| NO20033163L (no) | 2003-07-10 |
| KR20030070599A (ko) | 2003-08-30 |
| CA2434900A1 (fr) | 2002-08-22 |
| CN1226035C (zh) | 2005-11-09 |
| IL156819A (en) | 2008-03-20 |
| CZ301357B6 (cs) | 2010-01-27 |
| US20060205786A1 (en) | 2006-09-14 |
| BR0206918A (pt) | 2004-02-03 |
| KR100851256B1 (ko) | 2008-08-08 |
| TWI322011B (en) | 2010-03-21 |
| CA2434900C (fr) | 2010-10-05 |
| NO20033163D0 (no) | 2003-07-10 |
| PL362550A1 (en) | 2004-11-02 |
| EP1370262A1 (fr) | 2003-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108883110B (zh) | 使用食欲素-2受体拮抗剂治疗抑郁症的方法 | |
| US20020013372A1 (en) | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors | |
| HRP20000797A2 (en) | Combination therapy for treatment of refractory depression | |
| JP2007508236A (ja) | うつ病およびその他の情動障害を治療する方法 | |
| JP2018131462A (ja) | 認知機能を改善するための方法および組成物 | |
| HUT71329A (en) | Pharmaceutical compositions for inhibiting cns problems in post-menopausal women containing 2-phenyl-3-aroyl-benzothiophene-derivatives and process for their preparation | |
| SK9812003A3 (en) | New use of iloperidone | |
| Crapanzano et al. | Quetiapine in the anxiety dimension of mood disorders: a systematic review of the literature to support clinical practice | |
| KR20110021754A (ko) | 인지 결함 치료 방법 | |
| Gentile | Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials | |
| US20170119760A1 (en) | Use of masitinib for the treatment of progressive supranuclear palsy | |
| US20050234093A1 (en) | Treatment of depression and other affective disorders | |
| Geissen et al. | From High‐Throughput Cell Culture Screening to Mouse Model: Identification of New Inhibitor Classes against Prion Disease | |
| AU2002231766A1 (en) | New use of iloperidone | |
| AU2006201188B2 (en) | New use of iloperidone | |
| ZA200509356B (en) | Gaboxadol for treating depression and other affective disorders | |
| Shopsin et al. | Serotonin and depression | |
| CN1319532C (zh) | N－(吲哚羰基)哌嗪衍生物的用途 | |
| SK15002003A3 (sk) | Použitie 3-[1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)etyl]- 1,2,3,6-tetrahydropyridín-4-yl]-6-chlór-1H-indolu | |
| CA2529805A1 (fr) | Traitement de la depression et d'autres troubles affectifs | |
| JP2022524927A (ja) | 創薬のためのヒトスフェロイドの使用方法 | |
| Bubenikova-Valesova et al. | S48. 02-Effect of Serotonin-1A receptor on behavioral changes in animal model of schizophrenia-like behavior | |
| HK1092058A (en) | Treatment of depression and other affective disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Refused patent application |